Figure 1From: Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapyPercentages of patients with psoriatic arthritis achieving a Physician's Global Assessment (PGA) of "Clear/Almost clear" at baseline and week 12, stratified by history of anti-tumor necrosis factor therapy. Data are observed. IFX, infliximab; ETN, etanercept.Back to article page